Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)

Stefano BONORA; S Rusconi; Andrea CALCAGNO; MARGHERITA BRACCHI; O Viganò; JESSICA CUSATO; M Lanzafame; Alice TRENTALANGE; Letizia MARINARO; MARCO SICCARDI; ANTONIO D'AVOLIO; M Galli; Giovanni DI PERRI

doi:10.1093/jac/dkv208

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)

Stefano BONORA
, S Rusconi
, Andrea CALCAGNO
, MARGHERITA BRACCHI
, O Viganò
, JESSICA CUSATO
, M Lanzafame
, Alice TRENTALANGE
, Letizia MARINARO
, MARCO SICCARDI
, ANTONIO D'AVOLIO
, M Galli
, Giovanni DI PERRI

Dipartimento di Medicina Traslazionale

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

Abstract

Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization.

Lingua originale	Inglese
pagine (da-a)	3096-3099
Numero di pagine	4
Rivista	Journal of Antimicrobial Chemotherapy
Volume	70
Numero di pubblicazione	11
DOI	https://doi.org/10.1093/jac/dkv208
Stato di pubblicazione	Pubblicato - 2015

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

SDG 3 Salute e benessere

Accesso al documento

10.1093/jac/dkv208

https://hdl.handle.net/11579/216923

Altri file e collegamenti

handle

Cita questo

BONORA, S., Rusconi, S., CALCAGNO, A., BRACCHI, MARGHERITA., Viganò, O., CUSATO, JESSICA., Lanzafame, M., TRENTALANGE, A., MARINARO, L., SICCARDI, MARCO., D'AVOLIO, ANTONIO., Galli, M., & DI PERRI, G. (2015). Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). Journal of Antimicrobial Chemotherapy, 70(11), 3096-3099. https://doi.org/10.1093/jac/dkv208

@article{6f0c52607e10406ba8ca76f0e1514728,

title = "Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)",

abstract = "Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization.",

author = "Stefano BONORA and S Rusconi and Andrea CALCAGNO and MARGHERITA BRACCHI and O Vigan{\`o} and JESSICA CUSATO and M Lanzafame and Alice TRENTALANGE and Letizia MARINARO and MARCO SICCARDI and ANTONIO D'AVOLIO and M Galli and \{DI PERRI\}, Giovanni",

year = "2015",

doi = "10.1093/jac/dkv208",

language = "English",

volume = "70",

pages = "3096--3099",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "11",

}

BONORA, S, Rusconi, S, CALCAGNO, A, BRACCHI, MARGHERITA, Viganò, O, CUSATO, JESSICA, Lanzafame, M, TRENTALANGE, A, MARINARO, L, SICCARDI, MARCO, D'AVOLIO, ANTONIO, Galli, M & DI PERRI, G 2015, 'Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)', Journal of Antimicrobial Chemotherapy, vol. 70, n. 11, pagg. 3096-3099. https://doi.org/10.1093/jac/dkv208

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). / BONORA, Stefano; Rusconi, S; CALCAGNO, Andrea et al.
In: Journal of Antimicrobial Chemotherapy, Vol. 70, N. 11, 2015, pag. 3096-3099.

Risultato della ricerca: Contributo su rivista › Articolo in rivista › peer review

TY - JOUR

T1 - Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)

AU - BONORA, Stefano

AU - Rusconi, S

AU - CALCAGNO, Andrea

AU - BRACCHI, MARGHERITA

AU - Viganò, O

AU - CUSATO, JESSICA

AU - Lanzafame, M

AU - TRENTALANGE, Alice

AU - MARINARO, Letizia

AU - SICCARDI, MARCO

AU - D'AVOLIO, ANTONIO

AU - Galli, M

AU - DI PERRI, Giovanni

PY - 2015

Y1 - 2015

N2 - Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization.

AB - Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization.

UR - https://iris.uniupo.it/handle/11579/216923

U2 - 10.1093/jac/dkv208

DO - 10.1093/jac/dkv208

M3 - Article

SN - 0305-7453

VL - 70

SP - 3096

EP - 3099

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 11

ER -

Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study)

Abstract

OSS delle Nazioni Unite

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo